SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarc...

ver descrição completa

Detalhes bibliográficos
Autores: Martin-Richard, M, Carmona-Bayonas, A, Custodio, AB, Gallego, J, Jimenez-Fonseca, P, Reina, JJ, Richart, P, Rivera, F, Alsina, M, Sastre, J
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2020
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositório:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p2075
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2075
Access Level:Acceso aberto
Palavra-chave:Gastric cancer
Gastroesophageal junction adenocarcinoma
Diagnosis
Treatment
id ES_cfc26a4749db8d3c63c59eeecea07f3c
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p2075
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)Martin-Richard, MCarmona-Bayonas, ACustodio, ABGallego, JJimenez-Fonseca, PReina, JJRichart, PRivera, FAlsina, MSastre, JGastric cancerGastroesophageal junction adenocarcinomaDiagnosisTreatmentGastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.SPRINGER INTERNATIONAL PUBLISHING AG2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2075Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p20752026-06-14T12:41:47Z
dc.title.none.fl_str_mv SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
title SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
spellingShingle SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
Martin-Richard, M
Gastric cancer
Gastroesophageal junction adenocarcinoma
Diagnosis
Treatment
title_short SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
title_full SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
title_fullStr SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
title_full_unstemmed SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
title_sort SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
dc.creator.none.fl_str_mv Martin-Richard, M
Carmona-Bayonas, A
Custodio, AB
Gallego, J
Jimenez-Fonseca, P
Reina, JJ
Richart, P
Rivera, F
Alsina, M
Sastre, J
author Martin-Richard, M
author_facet Martin-Richard, M
Carmona-Bayonas, A
Custodio, AB
Gallego, J
Jimenez-Fonseca, P
Reina, JJ
Richart, P
Rivera, F
Alsina, M
Sastre, J
author_role author
author2 Carmona-Bayonas, A
Custodio, AB
Gallego, J
Jimenez-Fonseca, P
Reina, JJ
Richart, P
Rivera, F
Alsina, M
Sastre, J
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Gastric cancer
Gastroesophageal junction adenocarcinoma
Diagnosis
Treatment
topic Gastric cancer
Gastroesophageal junction adenocarcinoma
Diagnosis
Treatment
description Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2075
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2075
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
publisher.none.fl_str_mv SPRINGER INTERNATIONAL PUBLISHING AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420112265609216
score 15,811543

Registros relacionados